The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
Abstract
PURPOSE: To evaluate prospectively the effectiveness of epoetin alfa as an adjunct to chemotherapy in patients with cancer based on changes in quality-of-life parameters and hemoglobin levels, and to correlate these changes with antitumor response. PATIENTS AND METHODS: Two thousand three hundred seventy patients with nonmyeloid malignancies who received chemotherapy were enrolled onto this study from 621 US community-based practices. Patients received epoetin alfa 10,000 U three times weekly, which could be increased to 20,000 U three times weekly depending on the hemoglobin response at 4 weeks. Treatment continued for a maximum of 16 weeks in patients who showed evidence of hematologic response. RESULTS: Two thousand two hundred eighty-nine patients (97%) were eligible for efficacy analyses. Epoetin alfa therapy was associated with improved quality-of-life parameters; these improvements correlated significantly with hemoglobin levels and were independent of tumor response. Provider-reported Karnofsky performance scores did not correlate with the improved quality-of-life changes. Epoetin alfa therapy was also associated with a significant increase in hemoglobin levels and decrease in transfusion use. Tumor type, chemotherapy agent/regimen, prior chemotherapy, baseline hemoglobin level, and baseline erythropoietin level were not predictive of a positive response to treatment. Epoetin alfa was well tolerated. CONCLUSION: Epoetin alfa appears to have a beneficial impact on patient-reported functional capacity and quality of life in patients with cancer who received chemotherapy independent of tumor response. Concordantly, epoetin alfa appeared to increase hemoglobin levels and decrease transfusion use. Patients responded across all tumor types. The results suggest that epoetin alfa effectively improves functional outcomes in patients with cancer who receive chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Self-citationClinical applications of visual analogue scales: a critical review
McCormack, H. M., de L. Horne, D. J., & Sheather, S. (1988) · Psychological Medicine · doi:10.1017/s0033291700009934 · Cited by 2,108
Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(96)00274-6 · Cited by 1,964
Self-citationBrady, M. J., Cella, D. F., Mo, F., Bonomi, A. E., Tulsky, D. S., Lloyd, S. R., Deasy, S., Cobleigh, M., & Shiomoto, G. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.974 · Cited by 1,752
Self-citationGlaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S., & Vadhan-Raj, S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1218 · Cited by 693
Cella, D. F. (1997) · PubMed · Cited by 687
Self-citationDecreased Erythropoietin Response in Patients with the Anemia of Cancer
Miller, C. B., Jones, R. J., Piantadosi, S., Abeloff, M. D., & Spivak, J. L. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006143222401 · Cited by 658
Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer
Coates, A., Gebski, V., Bishop, J. F., Jeal, P. N., Woods, R. L., Snyder, R., Tattersall, M. H. N., Byrne, M., Harvey, V., Gill, G., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712103172402 · Cited by 537
Tannock, I. F., Boyd, N. F., DeBoer, G., Erlichman, C., Fine, S., Larocque, G., Mayers, C., Perrault, D., & Sutherland, H. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.9.1377 · Cited by 348
Measuring quality of life: 1995 update.
Cella, D. F., & Bonomi, A. E. (1995) · PubMed · Cited by 238
Self-citationPrediction of response to erythropoietin treatment in chronic anemia of cancer [see comments]
Ludwig, H., Fritz, E., Leitgeb, C., Pecherstorfer, M., Samonigg, H., & Schuster, J. (1994) · Blood · doi:10.1182/blood.v84.4.1056.1056 · Cited by 196
Erythropoietin for anaemia in cancer patients
Abels, R. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80281-3 · Cited by 185
Assessment of the quality of life of patients with advanced cancer
Gough, I. R., Furnival, C. M., Schilder, L., & Grove, W. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90042-1 · Cited by 178
Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin
Leitgeb, C., Pecherstorfer, M., Fritz, E., & Ludwig, H. (1994) · Cancer · doi:10.1002/1097-0142(19940515)73:10<2535::aid-cncr2820731014>3.0.co;2-5 · Cited by 167
Cancer-related anemia: its causes and characteristics.
Spivak, J. (1994) · PubMed · Cited by 107
Walsh (1995) · doi:10.1002/1097-0142(19951201)76:11
Cited by
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., Itri, L. M., & Cerami, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.19.10526 · Cited by 1,402
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Littlewood, T. J., Bajetta, E., Nortier, J. W. R., Vercammen, E., Rapoport, B., & for the Epoetin Alfa Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2865 · Cited by 974
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
Groopman, J. E., & Itri, L. M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.19.1616 · Cited by 929
Metadata
- Authors
- Demetri, G. D., Kris, M., Wade, J., Degos, L., & Cella, D.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-10
- Volume
- 16
- Issue
- 10
- Pages
- 3412-3425
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1884165293
- Cited by
- 751
- References
- 17
- FWCI
- 18.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.